Hemophilia significantly impacts lives beyond bleeding episodes, causing absenteeism, pain, and disability. India, with the ...

A multidisciplinary clinical team led by Professor Bernat Soria from the Institute of Bioengineering at the Miguel Hernández University of Elche (UMH, Spain) has developed a new method to deliver cell ...

Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.

Adding intravenous thrombolysis to endovascular treatment is not associated with an increased risk for bleeding or with changes in functional outcomes in patients with carotid tandem lesions.

MELBOURNE, Australia and INDIANAPOLIS, IN, USA I April 16, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces ...

A multidisciplinary clinical team led by Professor Bernat Soria from the Institute of Bioengineering at the Miguel Hernández ...